MRNA News
Archived Headlines
- Is the IPO market the pathway out of the forest? 04/23/20
- US IPO Weekly Recap: Two billion-dollar biotechs cap a mixed week for biotech IPOs 02/08/19
- Renaissance Capital's Updated 2018 US IPO Annual Review 01/04/19
- US IPO Weekly Recap: Biggest biotech breaks in 3-IPO week 12/07/18
- Moderna prices upsized IPO at $23 midpoint; largest biotech IPO ever 12/06/18
See more
Biotech IPOs close to beating Covid-19
Less than nine months after Covid-19 became an unwelcome household word, the virus may be close to being vanquished. A number of biotech IPOs are key players in vaccine development. Most prominent is headline grabber Moderna (MRNA), which went public in...read more
IPO Index touches all-time high, fueled by #4 holding Moderna
The Renaissance IPO Index rose 2.8% on Monday, and surpassed its all-time high in mid-day trading. The IPO Index is now up 12.9% for the year, outperforming the S&P 500 by 20 points, and the Nasdaq Composite by 10 points. The...read more
Llamas vs. Bats: Llama antibodies, the coronavirus, and the biotechs that benefit
Could llamas be the key to containing the coronavirus? Scientists from several institutions have developed a treatment using antibodies found in llamas,...read more
The 2020 IPO market is now up 43% from its lows, a promising sign for May
IPOs are leading the stock market's recovery. The Renaissance IPO Index has soared 42.6% from its mid-March low, compared to a 28.9% rebound for the S&P 500. The IPO Index, which is composed of the largest and most liquid IPOs over the past two years and...read more